welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
unknown status
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
status: unknown
purpose:We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
results: https://clinicaltrials.gov/ct2/show/results/NCT01772043
last updated: November 22, 2018
study details
study contacts
rareRelated
-
Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesThe study will include 120 participants ...
-
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-studyCarriers of Duchenne muscular dystrophy ...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
Whole Body Vibration Therapy in Boys With Duchenne Muscular DystrophyWhole-body vibration therapy (WBVT) is a...
-
Magnetic Resonance and Optical Imaging of Dystrophic and Damaged MuscleThe purpose of this research study is to...
-
Sarepta Receives Negative CHMP Re-examination Opinion for EteplirsenSarepta Therapeutics, Inc., a commercial...
-
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
-
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
